Clinical Trials · NCT06352892
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Amgen
- Enrollment
- 20
- Start date
- Apr 2024
- Locations
- 1 site, Hong Kong
- Primary endpoint
- Maximum Observed Plasma Concentration (Cmax) of Maridebart Cafraglutide